why choose us

Clinical Trials Search

Showing 13,510 of 132,366 result(s)
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

Status: Completed

Condition: Oropharynx Cancer

Interventions: Mon-Fri (5 days for 7 weeks), total 35 fractions over 35 treatment days of radiation therapy (RT)

Date: 2023-03-24

An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

Status: Completed

Condition: ADHD

Interventions: investigational game-play therapy

Date: 2023-03-24

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Status: Completed

Condition: Neovascular Age-related Macular Degeneration

Interventions: Single suprachoroidal injection of AXT107 (0.125 mg;eye)

Date: 2023-03-24

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Status: NOT_YET_RECRUITING

Condition: Metastatic Lung Non-Small Cell Carcinoma

Interventions: Undergo blood sample collection

Date: 2023-03-24

Hypertonic Saline Solution to Prevent Acute Kidney Injury After Heart Transplantation

Status: NOT_YET_RECRUITING

Condition: Heart Transplantation

Interventions: Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.

Date: 2023-03-24

Biobanking and New Biomolecular Metrics

Status: Completed

Condition: Melanoma (Skin)

Interventions: Liquid biopsy, re-biopsy, tissue biopsy

Date: 2023-03-24

Carbohydrate Rinsing and Caffeine Gum on Performance of Romanian Deadlifts Performance

Status: COMPLETED

Condition: Carbohydrate

Interventions: the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted

Date: 2023-03-24

Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease

Status: NOT_YET_RECRUITING

Condition: Chronic Lung Disease of Prematurity

Interventions: Administration of rfhSP-D

Date: 2023-03-24

Cevostamab Following CAR T Cell Therapy for RRMM

Status: Completed

Condition: Relapsed;Refractory Multiple Myeloma

Interventions: Cevostamab will be given as an IV infusion once every 3 weeks, starting roughly 10 weeks (day 70 +;- 4 days) post-CAR T cell infusion, with subje

Date: 2023-03-24